Yilong Wu, MD
Guangdong Provincial People's Hospital
Emerging Leaders
not ranked
Current Leaders
#586 pts
All-Time Leaders
#17838 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2007. 16 trials as lead/chair. How it works →
Trials led — by scientific impact
A Randomized, Double-Blind, Multicenter, Phase Ib/III Clinical Study on PD-L1 Monoclonal Antibody SHR-1316 or Placebo in Combination With Chemotherapy as Perioperative Treatment of Resectable Stage II or III Non-Small Cell Lung Cancer
Phase 3RecruitingJiangsu HengRui Medicine Co., Ltd.
11
impact
An Open, Multi-center, Single-arm Phase IIIb Confirmatory Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Vebreltinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Exon 14 Mutation
Phase 3RecruitingBeijing Pearl Biotechnology Limited Liability Company
10
impact
A Phase II, Open-label, Multicenter and Multi-cohorts Study to Evaluate the Efficacy and Safety of PLB1001 in Advanced Non-small Cell Lung Cancer With c-Met Dysregulation
Phase 2CompletedBeijing Pearl Biotechnology Limited Liability Company
3
impact
A Phase I/II, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759 in Chinese Patients With EGFRm+ NSCLC With Central Nervous System (CNS) Metastases
Phase 2CompletedLYZZ Alpha Holding Ltd
3
impact
An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant Genes
Phase 2ActiveSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2
impact
An Open-label, Multicenter Phase II Clinical Trial of SHR-1701 With or Without Chemotherapy in the Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Phase 2UnknownJiangsu HengRui Medicine Co., Ltd.
2
impact
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Patients With EGFR T790M Positive Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With EGFR TKIs
Phase 2UnknownHangzhou ACEA Pharmaceutical Research Co., Ltd.
2
impact
A Phase I Clinical Trial of IMMH-010 in Patients With Advanced Malignant Solid Tumors
Phase 1UnknownTianjin Chasesun Pharmaceutical Co., LTD
1
impact
Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC
Phase 3UnknownShanghai Yizhong Pharmaceutical Co., Ltd.
1
impact
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX42 (Anti-EGFR ADC) in Patients With Advanced/Metastatic Solid Tumors
Phase 1RecruitingShanghai Henlius Biotech
1
impact
A Phase Ib, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumour Activity of Volitinib in Combination With Gefitinib in Patients With Epidermal Growth Factor Receptor-mutated Non-small Cell Lung Cancer Who Have Progressed on Epidermal Growth Factor Receptor Inhibitor Treatment
Phase 1CompletedHutchison Medipharma Limited
1
impact
A Phase Ⅱ,Open-label, Single-line, Multiple Cohorts, Multicenter Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)
Phase 2ActiveAvistone Biotechnology Co., Ltd.
0
impact
A Randomized, Open-label, Controlled, Multi-Center Phase II/III Study to Assess the Efficacy and Safety of AZD3759 vs. a Standard of Care EGFR TKI, as First Line Treatment to EGFR Mutation Positive Advanced NSCLC With CNS Metastases
Phase 3CompletedAlpha Biopharma (Jiangsu) Co., Ltd.Study Chair
0
impact
A Randomized Study to Evaluate the Safety and Efficacy of Loading Dose of Bondronat Versus Standard Dose of Bondronat in Patients With Lung Cancer and Skeletal Metastasis Experiencing Moderate to Severe Pain
Phase 4TerminatedChinese Society of Lung Cancer
0
impact
A Phase II, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of SKB500 Combinations in Patients With Small Cell Lung Cancer
Phase 2RecruitingSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
0
impact
A Multicenter, Open-label, Randomized Clinical Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of GFH375 Monotherapy and Combination Therapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer Harboring KRAS G12D Mutation.
Phase 2Not Yet RecruitingGenfleet Therapeutics (Shanghai) Inc.Study Chair
0
impact
Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
N/ANot Yet RecruitingAstraZeneca
0
impact
A Multicenter, Randomized, Controlled, Open-label, Phase IIa Trial on Autologous Tumor Infiltrating Lymphocyte Injection (LM103 TILs) for the Adjuvant Treatment of Non-small Cell Lung Cancer With Negative Driver Gene Mutations
Phase 2RecruitingSuzhou BlueHorse Therapeutics Co., Ltd.Study Chair
0
impact
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
N/ARecruitingAlpha Biopharma (Jiangsu) Co., Ltd.
0
impact
An Open-Label, Multi-center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ICP-B794 in Patients With Advanced Solid Tumors
Phase 1Not Yet RecruitingBeijing InnoCare Pharma Tech Co., Ltd.
0
impact
0
impact
An Open-label, Randomized, Controlled, Multicenter Phase IIIb Clinical Study to Evaluate the Efficacy and Safety of Vebreltinib Enteric Capsule Combined With Platinum-based Doublet Chemotherapy Compared With Platinum-based Doublet Chemotherapy in Subjects With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Not Received Previous Systemic Treatment and MET-Positive
Phase 3RecruitingBeijing Pearl Biotechnology Limited Liability Company
0
impact
0
impact
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of QLS1103 in Subjects With Advanced Solid Tumors
Phase 1UnknownQilu Pharmaceutical Co., Ltd.
0
impact
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Combination With Toripalimab and JS006 in Patients With Advanced Malignancies
Phase 1WithdrawnShanghai Junshi Bioscience Co., Ltd.Study Chair
0
impact
An Apen-label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of BEBT-109 in Patients With EGFR Exon 20 Insertion Mutations in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 2RecruitingBeBetter Med Inc
0
impact
A Phase 1, Multi-Center, Open-Label Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BAT6021 as Mono Therapy or in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Phase 1TerminatedBio-Thera Solutions
0
impact
Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients
Phase 1UnknownBetta Pharmaceuticals Co., Ltd.
0
impact
An Open-label, Multicenter, Phase Ia/Ib Study to Evaluate the Safety, Tolerance and Preliminary Efficacy of IBI319 in Patients With Advanced Malignant Tumors
Phase 1UnknownInnovent Biologics (Suzhou) Co. Ltd.
0
impact
A Phase I Study on Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of LP-118 in Patients With Advanced Malignancies
Phase 1CompletedGuangzhou Lupeng Pharmaceutical Company LTD.Study Chair
0
impact
A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+/MET+ NSCLC
Phase 3ActiveHutchison Medipharma Limited
0
impact
A Phase I, Open-label, Multicenter, Dose Escalation and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase 1UnknownAvistone Biotechnology Co., Ltd.
0
impact
A Randomized Controlled, Double-blind, Multicenter, Phase III Clinical Study to Compare Efficacy and Safety of Abivertinib Maleate Versus First-line Standard Therapy EGFR-TKI in Patients With Advanced NSCLC With Sensitive EGFR Mutation
Phase 3UnknownHangzhou ACEA Pharmaceutical Research Co., Ltd.
0
impact
A Phase I Trial to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of SCC244 in Subjects With Advanced Solid Tumors
Phase 1CompletedHaihe Biopharma Co., Ltd.
0
impact
Single-arm,Multi-center,Phase II Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Mutation-positive Patients With Advanded NSCLC
Phase 2UnknownHangzhou ACEA Pharmaceutical Research Co., Ltd.
0
impact
A Study of Clinical and Genomic Analysis on Long-term Survivors of EGFR Mutation Positive Advanced Non-small-cell Lung Cancer Patients With Gefitinib Treatment in China
N/ATerminatedAstraZeneca
0
impact
A Phase I Open-label, Multicenter Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of PLB1001 in Patients With Met-positive (Met+) Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 1CompletedBeijing Pearl Biotechnology Limited Liability Company
0
impact
A Phase Ib, Open-label Study to Evaluate RAD001 as Monotherapy Treatment in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
Phase 2UnknownGuangdong Provincial People's Hospital
0
impact